C. Faustino

Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

E. Van Cutsem, J. Tabernero, M. Alsina, 2020, Gastric Cancer.

Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).

G. Beretta, J. Tabernero, M. Alsina, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.

G. Beretta, E. Van Cutsem, J. Tabernero, 2018, The Lancet. Oncology.

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer

J. Rodrigues, D. Martins, P. Redondo, 2022, Cureus.